SGLT2 inhibitors: The latest "New kids on the block"!

Diabetes Care

Volumn 38, Issue 3, 2015, Pages 352-354

  Cefalu, William T ^a   Riddle, Matthew C ^b  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CANAGLIFLOZIN; DAPAGLIFLOZIN; DAPAGLIFLOZIN PLUS METFORMIN; DAPAGLIFLOZIN PLUS SAXAGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; EMPAGLIFLOZIN PLUS LINAGLIPTIN; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LINAGLIPTIN; LOW DENSITY LIPOPROTEIN; MAGNESIUM; METFORMIN; METFORMIN PLUS SAXAGLIPTIN; PHOSPHATE; SAXAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SOTAGLIFLOZIN; SULFONYLUREA; TRIACYLGLYCEROL; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2;

BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; GENITAL TRACT INFECTION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSURIA; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOVOLEMIA; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; KETOACIDOSIS; KETOGENESIS; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; MICTURITION DISORDER; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; ORTHOSTATIC HYPOTENSION; PENIS DISEASE; POLLAKISURIA; RENAL CLEARANCE; SODIUM CLEARANCE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URINARY TRACT INFECTION; VAGINITIS; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 2; ECONOMICS; HEALTH CARE COSTS; HUMANS; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 84935010322     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-3048     Document Type: Note

References (16)

1. Dall TM, Yang W, Halder P, et al. The economic burden of elevated blood glucose levels in 2012: diagnosed and undiagnosed diabetes, gestational diabetes mellitus, and prediabetes. Diabetes Care 2014;37:3172- 3179.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38:140-149.
3. Leiter LA, Yoon K-H, Arias P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: A randomized, double-blind, phase 3 study. Diabetes Care 2015;38:355-364.
4. Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S; Study 05 Group. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: A 24-week randomized, doubleblind clinical trial. Diabetes Care 2015;38:365- 372.
5. Abdul-Ghani M. Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes? Diabetes Care 2015;38:373-375.
6. Rosenstock J, Hansen L, Zee P, et al. Dual addon therapy in type 2 diabetes poorly controlled with metformin monotherapy: A randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 2015;38:376-383.
7. De Fronzo RA, Lewin A, Patel S, et al. Combination ofempagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 2015;38:384-393.
8. Lewin A, De Fronzo R, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care 2015;38:394-402.
9. Neal B, Perkovic V, de Zeeuw D, et al.; CANVAS Trial Collaborative Group. Efficacy and safety of canagliflozin, an inhibitor of sodium- glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care 2015;38:403-411.
10. Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A randomized, double-blind, placebo-controlled pilot study. Diabetes Care 2015;38:412-419.
11. Tikkanen I, Narko K, Zeller C, et al.; EMPAREG BP Investigators. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 2015;38:420- 428.
12. Majewski C, Bakris GL. Blood pressure reduction: An added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes. Diabetes Care 2015;38:429- 430.
13. Rosenstock J, Cefalu WT, Lapuerta P, et al. Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy. Diabetes Care 2015;38:431-438.
14. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: Rationale and clinical prospects. Nat Rev Endocrinol 2012;8:495-502.
15. Riser Taylor S, Harris KB. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Pharmacotherapy 2013;33:984-999.
16. Leiter LA, Cefalu WT, de Bruin TW, Gause- Nilsson I, Sugg J, Parikh SJ. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: A 24-week, multicenter, randomized, doubleblind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc 2014;62:1252-1262.